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In Brief
Varanita et al. show that a mouse model
of controlled overexpression of the
master mitochondrial cristae biogenetic
factor Opa1 resists skeletal muscle
atrophy, heart and brain ischemic
damage, and massive liver apoptosis by
blunting mitochondrial dysfunction and
cytochrome c release. Together with the
accompanying paper by Civiletto et al.,
the authors offer a proof of principle of the
potential for therapies targeting cristae
remodeling in sporadic and genetic
diseases.
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Mitochondrial morphological and ultrastructural
changes occur during apoptosis and autophagy,
but whether they are relevant in vivo for tissue
response to damage is unclear. Here we investigate
the role of the optic atrophy 1 (OPA1)-dependent
cristae remodeling pathway in vivo and provide
evidence that it regulates the response of multiple
tissues to apoptotic, necrotic, and atrophic stimuli.
Genetic inhibition of the cristae remodeling pathway
in vivo does not affect development, but protects
mice from denervation-induced muscular atrophy,
ischemic heart and brain damage, as well as hepa-
tocellular apoptosis. Mechanistically, OPA1-depen-
dent mitochondrial cristae stabilization increases
mitochondrial respiratory efficiency and blunts mito-
chondrial dysfunction, cytochrome c release, and
reactive oxygen species production. Our results indi-
cate that the OPA1-dependent cristae remodeling
pathway is a fundamental, targetable determinant
of tissue damage in vivo.
INTRODUCTION
Mitochondria are crucial organelles in energy conversion (Danial
et al., 2003; Rizzuto et al., 2000), and, not surprisingly, impaired
mitochondrial function affects organs where energy demand is
high, like heart, skeletal muscle, and brain (DiMauro and Schon,
2003). Cellular damage is not only the consequence ofmitochon-
drial bioenergetic failure, given that these organelles also play a
crucial role in apoptosis, when in response to several stimuli they
release cytochrome c and other pro-apoptotic proteins that
execute cell demise (Wang, 2001). Mitochondrial permeabiliza-834 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authorstion during apoptosis is controlled by members of the Bcl-2 fam-
ily and is accompanied by bothmorphological and ultrastructural
changes of the organelle (Danial and Korsmeyer, 2004; Wasilew-
ski and Scorrano, 2009). Mitochondrial network fragmentation
and cristae remodeling with widening of cristae junctions are
both required for the complete release of cytochrome c (Scor-
rano et al., 2002; Yamaguchi et al., 2008).
A family of dynamin-related large GTPases controls mitochon-
drial fusion and fission (Griparic and van der Bliek, 2001). Fission
occurs upon the recruitment of dynamin-related protein 1 (DRP1)
on the outer mitochondrial membrane (OMM) (Cereghetti et al.,
2008), where it binds to its adaptors, including fission 1 (Fis1),
mitochondrial fission factor (MFF), and mitochondrial division
(Mid) 49 and 51 (Palmer et al., 2011). Mitochondrial fusion is
controlled by mitofusins (MFN) 1 and 2 in the OMM and by
OPA1 in the inner mitochondrial membrane (IMM) (Chen et al.,
2003; Santel et al., 2003; Cipolat et al., 2004). The IMM can be
divided in two subcompartments: the so-called ‘‘boundary
membrane’’ and the cristae, separated from the former by nar-
row tubular junctions (Frey andMannella, 2000). Upon activation
of mitochondrial respiration, cristae transition from the orthodox
to the condensed morphology (Hackenbrock, 1966), and during
apoptosis they remodel in response to pro-apoptotic BH3-only
BCL-2 family members such as BID, BIM-S, and BNIP3, inde-
pendently from outer membrane permeabilization (Scorrano
et al., 2002; Yamaguchi et al., 2008; Landes et al., 2010). In addi-
tion to, and independently from, its role in mitochondrial fusion,
OPA1 regulates apoptotic cristae remodeling by forming oligo-
mers that participate in cristae junction formation and mainte-
nance (Frezza et al., 2006; Cipolat et al., 2006). Moreover,
OPA1, by maintaining mitochondrial cristae morphology, has a
direct metabolic effect, stabilizing respiratory chain supercom-
plexes (RCSs) (Cogliati et al., 2013).
The identification of the key role of OPA1 in cristae remodeling
suggests a potential approach tomanipulate this process in vivo;
however, constitutive as well as conditional tissue-specificOpa1
ablation in the mouse is lethal (Zhang et al., 2011; Davies et al.,
Figure 1. Opa1tg Mice Are Viable, Fertile, and Grow Normally
(A) Schematic representation of targeted transgenesis strategy into the
permissive hypoxanthine phosphoribosyltransferase (HPRT) locus. The tar-
geted vector includes a 50 HPRT homology arm, b-actin promoter, the trans-
gene cDNA OPA1 isoform 1, and 30 HPRT homology arm including a part of
HPRT promoter and a homologous region to the mouse HPRT locus. The
targeting construct is linearized before electroporation into BPES cells. Ho-
mologous recombination of the 30 arm reconstitutes a functional HPRT gene,
allowing the selection of targeted BPES cells on stringent hypoxanthine-
aminopterin-thymidine (HAT) conditions.
(B) PCR analysis of genomic DNA from wild-type (WT), heterozygous
(Opa1+/), and homozygous (Opa1+/+) Opa1tg mouse tail.
(C) Equal amounts of protein from tissues of the indicated genotypes were
separated by SDS-PAGE and immunoblotted with the indicated antibodies.
(D) Densitometric analysis of OPA1 protein level in tissue from heart and
muscle. Data represent average ± SEM (n = 7 for each group). *p < 0.05 in an
unpaired two-sample Student’s t test.
(E) Average ± SEM body weight of 5-month-old male (n = 34 for each group)
and female (n = 13 for each group) and of 9-month-old male (n = 18 for each
group) and female (n = 16 for each group) C57/Bl6 littermates of the indicated
genotype. *p < 0.05 in a two-tailed ANOVA test.
(F) Kaplan-Meier censorial analysis of C57/Bl6 mice of the indicated genotype
(n = 30 male and n = 26 female littermates).
See also Figure S1.2007), and uncontrolled OPA1 overexpression is toxic (Cipolat
et al., 2004), complicating the generation of suitable in vivo
models. To circumvent these difficulties, we recently generated
a mouse model where a transgene carrying Opa1 isoform 1 un-Cder the control of the ubiquitous human b-actin promoter was
purposely targeted to a permissive X chromosome region,
without altering endogenous gene expression (Cogliati et al.,
2013). We capitalized on this mouse model to investigate the
role of the OPA1-dependent cristae remodeling pathway in vivo.
Our data indicate that mild OPA1 overexpression is compatible
with life and blunts damage of highly metabolically active organs
in response to apoptotic, necrotic, and atrophic stimuli by
reducing cytochrome c release and mitochondrial dysfunction,
thereby highlighting the importance of cristae shape in tissue ho-
meostasis and non-developmental cell death.
RESULTS
Controlled OPA1 Overexpression Is Compatible with
Embryonic Development and Does Not Affect Lifespan
Opa1-overexpressing mice (Opa1tg) generated by targeting a
single copy of murine Opa1 isoform 1 driven by human b actin
promoter immediately upstream of the mouse X chromosome
Hprt locus (Cogliati et al., 2013) (Figures 1A and 1B) were back-
crossed for more than 10 generations in C57/Bl6J and SV129
genetic backgrounds. Opa1tg mice were born at the expected
Mendelian frequency, developed and grew normally, and were
apparently indistinguishable from sex- and age-matched wild-
type (WT) littermates. The expected mild (1.5-fold), but statisti-
cally significant, OPA1 overexpression was detected by western
blot analysis in all the tissue tested (Figures 1C and 1D).
Conversely, expression levels of the key mitochondrial fusion-
fission proteins as well as of the pro- and anti-apoptotic Bcl-2
family proteins were unaltered (Figures S1A and S1B). While
Opa1tg andWT littermates’ body weight was comparable during
the first 60 days after birth (Figure S1C), in the obesity-prone
C57/Bl6J strain (Almind and Kahn, 2004) the body weight of 5-
to 9-month-old Opa1tg individuals was slightly, but significantly,
reduced in respect to their WT littermates (Figure 1E). This effect
of OPA overexpression was not recorded in the Sv129 back-
ground (Figure S1D) and had no effect (beneficial or detrimental)
on the overall survival as shown by a Kaplan-Meyer censorial
analysis (Figures 1F and 1G). In conclusion, Opa1tg mice are
viable and display no apparent major phenotype, indicating
that a mild OPA1 overexpression is compatible with life and
fertility.
Physiological Heart Hypertrophy in 9-Month-Old Opa1tg
Mice
In order to address the long-termeffects ofOPA1overexpression,
we aged the Opa1tg animals and analyzed morphologically and
histologically several organs at different time points. Upon gross
inspection, hearts of 9-month-old Opa1tg mice appeared bigger
than their WT littermates (Figure 2A). Accordingly, the heart/
body weight ratio (Figure 2B) and the cardiomyocyte cross-
sectional area (Figures 2C and 2D) were increased in 9-month-
old Opa1tg mice, but not in younger animals (Figures S2A
and S2B). Since other parenchymal organs, such as liver and kid-
ney, were not enlarged, as revealed by post-mortem as well as
in vivo echography inspection (Figures S2D–S2F), we concluded
that the hypertrophy was specific to the heart. The observed hy-
pertrophy was not accompanied by echocardiographic signs of
cardiac dysfunction at 9 (Figures 2E and 2F) as well as at 5ell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authors 835
Figure 2. Opa1tg Mice Develop a Non-pathological Cardiac Hypertrophy
(A) Representative photographs of hearts dissected from littermates of the indicated genotype and age. Scale bars, 0.5 cm.
(B) Average ± SEM heart/body weight ratio in littermates of the indicated genotype and age (n = 8 in each group). *p < 0.05 in a two-tailed ANOVA test versus
5 months Opa1tg dataset.
(C) Representative detail confocal images of left ventricular cryosections stained for dystrophin from 9-month-oldmice of the indicated genotype. Scale bar, 25 mm.
(D) Experiments were as in (C). Data represent mean ± SEM of four independent experiments. *p < 0.05 in an unpaired two-sample Student’s t test.
(E) Echocardiographic long axis view of hearts from 9-month-old littermates of the indicated genotype. LV, left ventricle; A, aorta.
(F) Experiments were as in (E). Data represent mean ± SEM percentage of cardiac ejection fraction (EF) and shortening (SF) of four independent experiments.
(G) H&E staining of ventricular cryosections from 9-month-old littermates of the indicated genotype. Scale bars, 100 mm.
(H) Representative immunofluorescence images of ventricular cryosections stained for atrial natriuretic peptide (ANP) from 9-month-old littermates of the
indicated genotype. Scale bar, 100 mm.
(I) Data represent average ± SEM of ANPmRNA levels determined by RT-PCR in 4- and 9-month-old littermates of the indicated genotype (n = 4 for each group).
(J) Representative immunofluorescence images of ventricular cryosections stained for collagen I from 9-month-old littermates of the indicated genotype. Scale
bar, 100 mm.
(K) Experiments were as in (J). Data represent mean ± SEM of four independent experiments.
See also Figure S2.(Figure S2G) months of age. Echocardiographic speckle tracking
analysis to assess myocardial performance/load relationship
excluded that Opa1tg hearts contract against an increased after-
load, indicative of increased blood pressure, a major cause of
heart hypertrophy: the time to peak (TtPk) of myocardial short-
ening of longitudinal and radial strainswere comparable inOpa1tg
and WT hearts (longitudinal strain TtPk, 81.6 ± 6.15 ms in Opa1tg
versus 63.0 ± 4.1 ms in WT; radial strain TtPk, 50.0 ± 33.4 ms in
Opa1tg versus 49.3 ± 20.1ms inWT). All the tests for pathological
hypertrophy were negative: histology of 9-month-old WT and
Opa1tg hearts was superimposable (Figure 2G), the fetal hyper-836 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authorstrophy gene atrial natriuretic peptide (ANP) (Du, 2007) was not
induced,as judgedby immunofluorescenceandRT-PCRanalysis
(Figures 2Hand2I), andheartswere also negative for theother hy-
pertrophy gene b-myosin heavy chain (b-MHC) (Figure S2H).
Furthermore, the lack of collagen-I immunostaining excluded
interstitial fibrosis (Figures 2J and 2K) in 9-month-old Opa1tg
hearts. Finally, since mitochondrial dysmorphology and dysfunc-
tion characterize pathological cardiac hypertrophy (Abel and
Doenst, 2011), we set out to investigate mitochondrial shape
and activity in 9-month-old Opa1tg hearts. Mitochondrial ultra-
structure, evaluated by electron microscopy (EM; Figure S2I),
Figure 3. Opa1tg Mice Are Protected from Denervation-Induced Muscle Atrophy
(A) H&E staining of control and 10-days-denervated gastrocnemial cryosections from 9-month-old littermates of the indicated genotype. Scale bars, 50 mm.
(B) Experiments were as in (A). Muscle loss 10 days after denervation was quantified by cross-sectional area (CSA) measurement of innervated and denervated
fibers. Data represent mean ± SEM of five independent experiments. *p < 0.05 in an unpaired two-sample Student’s t test.
(C–E) Data represent average ± SEM of the indicated mRNA levels determined by RT-PCR in littermates of the indicated genotype treated as indicated (n = 5 for
each group). *p < 0.05 in an unpaired two-sample Student’s t test.
(F) Data are average ± SEM of five independent experiments of TMRM fluorescence analysis over mitochondrial regions in fibers isolated from FDB of the
indicated genotype treated as indicated.
(G) Equal amounts (30 mg) of protein from gastrocnemius isolated from littermates of the indicated genotype treated as indicated were separated by SDS-PAGE
and immunoblotted using the indicated antibodies. Den., denervated.
See also Figure S3.biogenesis, measured by real-time PCR analysis of mRNA levels
of adenine translocase 1 (ANT1), controlled by the master bioge-
netic factor PGC1a (Figure S2J), as well as bioenergetics, indi-
cated by biochemical and histological respiratory chain com-
plexes (RCCs) activity measurements (Figures S2K and S2L),
were not impaired. Complex III and IV activities were in fact
increased, probably as a consequence of RCS stabilization by
OPA1 (Cogliati et al., 2013). Thus, 9-month-old Opa1tg animals
display physiological heart hypertrophy, and indeed they perform
slightly, but significantly, better than their WT littermates on a
treadmill exercise test (Civiletto et al., 2015 [this issue of Cell
Metabolism]).
Opa1tg Mice Are Protected from Denervation-Induced
Muscular Atrophy
Since cardiomyocyte size results from the balance between tro-
phic and atrophic processes, we wished to investigate if OPA1Coverexpression counteracted the atrophic program that in mus-
cle activates autophagy and requires mitochondrial fragmenta-
tion (Romanello et al., 2010) and in heart is exacerbated during
aging when it is accompanied by lipofuscinosis (De Meyer et al.,
2010). We therefore turned to ischiectomy-induced muscle
loss, an established model of muscle atrophy where mitochon-
dria are targets of degradation and active participants in
myonuclear apoptosis (Siu and Alway, 2005; Sandri et al.,
2006; Adhihetty et al., 2007). Histological analysis did not reveal
signs of inflammation, degeneration, or regeneration in gastroc-
nemius sections from control or 10-day-denervated 5-month-
old WT and Opa1tg mice (Figure 3A), but Opa1tg mice were
significantly protected from denervation-induced muscle mass
loss (Figure 3B) in both oxidative or glycolytic fibers (Figure S3A).
Accordingly, induction of Muscle Ring-Finger protein 1 (Murf1),
the muscle-specific atrophy-related ubiquitin ligase that con-
trols degradation of sarcomeric proteins (Sandri, 2013), wasell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authors 837
Figure 4. Opa1tg Mice Are Protected from
Ischemic Damage
(A) Schematic representation of the experimental
ischemia-reperfusion protocol used.
(B) Data represent average ± SEM of eight inde-
pendent experiments of lactate dehydrogenase
(LDH) release during reperfusion in 5-month-old
littermates of the indicated genotype, sex, and
background (n = 8 for each group). *p < 0.05 in a
two-tailed ANOVA test.
(C) Equal amounts (30 mg) of heart protein from
littermates of the indicated genotype treated as
indicated were separated by SDS-PAGE and im-
munoblotted using the indicated antibodies.
(D) Representative images of TTC-stained whole
brains from 3-month-old Sv129 female littermates
of the indicated genotype mice 72 hr after middle
cerebral artery occlusion (MCAo).
(E) Representative TTC-stained 250-mm brain
sections from 3-month-old Sv129 female litter-
mates of the indicated genotype 72 hr after MCAo.
Slices are aligned from anterior to posterior.
(F) Data represent average ± SEM of four inde-
pendent experiments carried out as in (E). *p < 0.05
in an unpaired two-sample Student’s t test.reduced in denervated Opa1tg muscles (Figure 3C), suggesting
that OPA1 overexpression inhibits the atrophic program. Mech-
anistically, however, expression levels of atrophy-related genes
of the ubiquitin-proteasome and autophagy-lysosome families
that control myofiber size during disuse muscle atrophy (Powers
et al., 2007; Sandri, 2008) were comparable in control and
denervated WT and Opa1tg muscles (Figures 3D and 3E), and
autophagic flux was not altered in mouse adult fibroblasts
(MAFs) derived from Opa1tg mice (Figures S3B and S3C). We
therefore investigated mitochondrial biogenesis and function
in control and denervated muscles. Levels of the mitochondrial
dynamics genes (except, of course, Opa1) and of the mitochon-
driobiogenetic factor Pgc1a were not changed (Figure S3D),
suggesting that OPA1 overexpression does not induce bio-
genesis. Conversely, an established assay of mitochondrial
dysfunction (Irwin et al., 2003) that characterizes muscle atro-
phy (Seo et al., 2010) revealed that Opa1tg fibers were protected
from denervation-inducedmitochondrial dysfunction (Figure 3F).
This assay reveals latent mitochondrial dysfunction and was
more sensitive than histological and biochemical cytochrome
c oxidase (COX) activity measurements, which resulted normal
in gastrocnemius (Figures S3E and S3F) and in soleus (Fig-
ure S3G) in both genotypes, also after denervation. We could
correlate the observed protection to the levels of the long
OPA1 form that supports most of OPA1 functions (Anand
et al., 2014) and that was almost completely degraded in dener-
vated WT, but not Opa1tg, muscles (Figure 3G; long OPA1
represented only 4% of total OPA1 in WT, but 17% in
Opa1tg-denervated muscles). Notably, the protection from
muscular atrophy was long term, as shown by the preservation
of muscular function and mass by OPA1 overexpression in a
severe model of myopathy caused by skeletal muscle COX 15
(Cox15sm/sm) ablation (see the accompanying manuscript by
Civiletto et al. [2015] [this issue of Cell Metabolism]). Thus,
OPA1 overexpression protects from acute and chronic muscle
atrophy by blunting mitochondrial dysfunction and expression838 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authorsof the critical ubiquitin ligase MuRF1, without altering the auto-
phagic program or inducing mitochondrial biogenesis.
Opa1tg Mice Are Protected from Ischemic Damage
The protection of Opa1tg mice from muscular atrophy prompted
us to investigate other models of tissue damage where mito-
chondria play a central role. Myocardial infarction, besides being
the leading cause of death in theWestern world, is characterized
by central necrosis and peripheral apoptosis, two processes in
which mitochondrial dysfunction participates during both the
ischemic and the reperfusion phases (Murphy and Steenbergen,
2008). By using a classical Langendorff-perfused heart prepara-
tion, we subjected hearts of 5-month-old mice to 40 min of
ischemia followed by 15 min of reperfusion (I/R; Figure 4A) (Bar-
bato et al., 1996) and assessed cardiac injury by measuring
lactate dehydrogenase (LDH) release during the reperfusion
period. OPA1 overexpression reduced the amount of released
LDH in male and female C57/Bl6 and SV129 mice (Figure 4B),
thereby excluding potentially confounding effects of genetic
background and gender that influence the response to heart
ischemia (Du, 2004). Similar to what was observed during skel-
etal muscle denervation, I/R was accompanied by long OPA1
degradation in WT, but not Opa1tg, hearts (Figure 4C; long
OPA1 represents only 0.6% of total OPA1 in WT and 10%
inOpa1tg hearts). The protection from ischemia was not confined
to heart, since infarct volume, assessed in triphenyl tetrazolium
chloride (TTC)-stained serial sections from brains 3 days after
middle cerebral artery occlusion (MCAo) (Colak et al., 2011),
was significantly reduced inOpa1tgmice (Figures 4D–4F). These
results indicate that mild OPA1 overexpression protects heart
and brain from ischemic damage.
Opa1tg Are Less Susceptible to Fas-Induced Liver
Damage
The protection afforded by OPA1 from heart and brain
ischemia corroborates early findings that implicated OPA1
Figure 5. Opa1tg Mice Are Protected from
Fas-Induced Apoptotic Liver Damage
(A) Representative images of H&E-stained
paraffin-embedded liver sections from littermates
of the indicated genotype. Where indicated mice
were tail vein injected with 0.25 mg/g anti-Fas
antibody (Fas), sacrificed after 24 hr, and livers
were explanted for histology. Scale bar, 50 mm.
(B) Experiments were as in (A), except that paraffin-
embedded liver sections were TUNEL stained.
Arrows indicate TUNEL-positive hepatocytes.
Scale bar, 25 mm.
(C) Data represent average ± SEM of four inde-
pendent experiments carried out as in (B). At least
30 images per group per experiment were
analyzed. *p < 0.05 in an unpaired two-sample
Student’s t test.
(D) Representative confocal images of liver cry-
osections from littermates of the indicated
genotypes treated as indicated and immuno-
stained for cytochrome c (green) and TOM20
(red). The boxed areas are magnified 53. Scale
bar, 20 mm.
(E and F) Plasma ALT (E) or AST (F) levels in mice of
the indicated genotypes at the indicated time
points after tail vein injection of 0.25 mg/g anti-Fas
antibody. Data represent average ± SEM (n = 7 in
E, and n = 8 in F, for each group). *p < 0.05 in an
unpaired ANOVA test.
See also Figure S4.and OPA1-dependent cristae remodeling in cell death. How-
ever, we wished to further challenge this hypothesis by
turning to a model of in vivo apoptosis. Fas receptor activa-
tion in the liver by means of tail vein injection of anti-Fas-acti-
vating antibodies is a well-characterized model of severe
apoptotic liver damage (Ogasawara et al., 1993) where Fas-
induced death is dependent on mitochondria (Yin et al.,
1999; Wei et al., 2000). While liver histology was not different
in 3-month-old BL6 WT and Opa1tg mice, 24 hr after tail vein
injection of an activating anti-Fas antibody, damage was
greatly decreased in Opa1tg livers, where the lobular architec-
ture was preserved and the hemorrhagic infiltrates reduced
(Figure 5A). Accordingly, TUNEL staining revealed a signifi-
cant reduction in apoptotic cell death in Opa1tg livers (Figures
5B and 5C). Also, Sv129 Opa1tg mice were less susceptible
than their WT littermates to the same anti-Fas antibody-Cell Metabolism 21, 834–induced liver damage, as judged by sur-
vival and liver histology (Figure S4).
Mechanistically, the protection afforded
by OPA1 correlated with the inhibition
of cytochrome c release from mitochon-
dria, as revealed by the analysis of
subcellular cytochrome c distribution in
Fas-treated WT and Opa1tg livers (Fig-
ure 5D). Consistently, the increase in
plasma alanine and aspartate transami-
nases (ALT and AST) levels, a liver
damage indicator, was significantly
lower in Fas-treated Opa1tg mice versus
their WT-treated littermates (Figures 5Eand 5F). Thus, OPA1 overexpression inhibits mitochondrial-
dependent hepatocyte apoptosis in vivo.
Opa1tg Mitochondria Are Resistant to Cristae
Remodeling and Cytochrome C Release
We next wished to address mechanistically how OPA1 overex-
pression protected from these multiple and different death
stimuli in vivo. In immortalized fibroblasts, OPA1 modulates
mitochondrial apoptosis (Frezza et al., 2006) as well as RCS as-
sembly and mitochondrial respiration efficiency (Cogliati et al.,
2013). We therefore sought to verify if the same held true in pri-
mary tissues. As expected, mitochondria were longer in primary
myoblasts prepared from Opa1tg diaphragms (Figures 6A and
6B), and cristae tighter in hearts (Figures 6C and 6D) as well as
in other organs (data not shown) fromOpa1tgmice. Functionally,
Opa1tg primary fibroblasts produced less mitochondrial reactive844, June 2, 2015 ª2015 The Authors 839
Figure 6. Opa1tg Mitochondria Are Resistant to Apoptotic Cristae Remodeling and Cytochrome C Release
(A) Representative confocal images of mitochondrially targeted YFP transfected in primary myoblasts of the indicated genotype. Scale bar, 20 mm.
(B) Data represent average ± SEM of four independent experiments (30 cells/experiment) of mitochondrial major axis length calculation in experiments as in (A).
*p < 0.05 in an unpaired two-sample Student’s t test.
(C) Representative electron micrographs of hearts of the indicated genotype. Scale bar, 500 nm.
(D) Morphometric analysis of cristae width in 80 randomly selected mitochondria of 5-month-old hearts from WT and Opa1tgmice. *p < 0.05 in an unpaired two-
sample Student’s t test.
(E) Fold increase in MitoSOX fluorescence after treatment with antimycin A (10 mM, 20 min) in cells incubated for 24 hr in DMEM supplemented with the indicated
monosaccharides. Data represent average ± SEM of four independent experiments. *p < 0.05 in an unpaired two-sample Student’s t test.
(F) Mitochondria isolated from livers of the indicated genotypes were treated for the indicated times with 40 pmol/mg cBID, and cytochrome c release was
measured by ELISA. Data represent average ± SEM of five independent experiments.
(G) Ascorbate/TMPD-driven respiration of purified liver mitochondria of the indicated genotypes treated where indicated for 15 min with cBID. Data represent
average ± SEM of four independent experiments. *p < 0.05 in an unpaired two-sample Student’s t test.
(H) Purified muscle mitochondria of the indicated genotype were treated for the indicated times with cBID, and, where indicated, 10 mM EDC was added. Equal
amounts (30 mg) of proteins were separated by SDS-PAGE and immunoblotted using the indicated antibodies.
(I) Densitometric analysis of OPA1 oligomers. Experiments were as in (H). Data represent average ± SEM of five independent experiments. *p < 0.05 in a two-way
ANOVA with the corresponding time point WT or between the indicated samples.
See also Figure S5.oxygen species (ROS) when supplied with excess glucose or
galactose that forces mitochondrial respiration (Figure 6E). This
reduction of ROS production was not caused by desensitization
of the mitochondrial permeability transition pore (PTP) that ag-
gravates ROS production and apoptosis (Basso et al., 2005),
since complex IV-dependent mitochondrial respiration (Fig-
ure S5A), membrane potential (Figure S5B), and basal and
maximal calcium retention capacity (CRC; a sensitive indicator
of PTP threshold; Figures S5C and S5D) were superimposable
in WT and Opa1tg mitochondria. Conversely, respiratory control
ratio (RCR) ofOpa1tg liver and fibroblast mitochondria energized
with glutamate/malate is higher (Cogliati et al., 2013), supporting
reduced ROS production from stabilized RCSs. In addition to840 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authorsreduced ROS production, Opa1tg mitochondria were releasing
less cytochrome c in an established assay of mitochondrial per-
meabilization based on recombinant active caspase-cleaved
BID (cBID) (Scorrano et al., 2002; Frezza et al., 2006) (Figure 6F),
notwithstanding that BAK activation (measured as its oligomeri-
zation) in response to cBID was comparable in WT and Opa1tg
mitochondria (Figure S5E). To verify if cytochrome cmobilization
from the cristae was blunted in Opa1tg mitochondria we
measured the ratio of ascorbate (asc)-driven over tetramethyl-
p-phenylenediamine (TMPD)-driven respiration, an established
assay of submitochondrial cytochrome c localization (Scorrano
et al., 2002). While basal asc/TMPD ratios were comparable,
cBID increased it only in WTmitochondria (Figure 6G), indicating
that the apoptotic redistribution of cytochrome c was blocked
in Opa1tg mitochondria. Accordingly, the OPA1 oligomers tar-
geted by cBID to trigger cristae remodeling and cytochrome c
redistribution (Frezza et al., 2006) were stabilized inOpa1tgmito-
chondria (Figures 6H, 6I, and S5E). Taken together these results
indicate that mild OPA1 overexpression blunts apoptotic cristae
remodeling in vivo.
DISCUSSION
The field of mitochondrial dynamics blossomed when the pro-
cesses of cristae remodeling and mitochondrial fragmentation
during apoptosis were discovered (Scorrano et al., 2002; Frank
et al., 2001; Martinou et al., 1999). The discovery that OPA1 con-
trols cristae remodeling (Frezza et al., 2006) and RCS assembly
and stability (Cogliati et al., 2013) offered a conceptual frame-
work to explore whether OPA1 overexpression interfered with
cell death in vivo. Our results indicate that mild OPA1 overex-
pression is compatible with life and protects mice from multiple
form of damage, implicating cristae remodeling in myocardial
and brain infarction, hepatocellular apoptosis, and muscular
atrophy.
In order to investigate the role of cristae remodeling in vivo we
elected to modulate levels of its master regulator OPA1. Not
surprisingly, given the crucial role of this protein in mitochondrial
physiology, its ablation is lethal early during intrauterine develop-
ment (Davies et al., 2007), and its inducible deletion in differenti-
ated tissues such as brain and skeletal muscle is similarly fatal
(data not shown). We therefore turned to a different approach
and generated a mouse model of targeted, controlled Opa1
overexpression (Cogliati et al., 2013) where we could avoid the
paradoxical toxic effects of high OPA1 levels (Cipolat et al.,
2004).
Opa1 overexpression does not impair fertility, intrauterine
development, adult life, and lifespan, a surprising lack of effect
for a gene with a documented anti-apoptotic effect. Conversely,
in the BL6 background it slightly, but significantly, lowered body
weight at 5–9 months, and in both BL6 and Sv129 backgrounds
it granted protection from a panoply of insults to different tissues.
It shall be mentioned, however, that in the Sv129 background
the incidence of spontaneous cancer is increased, and lifespan
is accordingly reduced (data not shown), unlike the crucial
apoptosis inhibitors Bcl-2 and Bcl-XL whose overexpression
does not promote cancer per se, except when it is confined in
the B cell compartment (Frenzel et al., 2009; Pena et al., 1998).
The small effect of Opa1 overexpression on body weight might
be a consequence of its role on mitochondrial bioenergetics,
or it could result from a yet-unclear effect of cristae shape on
intermediate metabolism. In any case, it suggests that the rela-
tionship between cristae shape and weight control shall be
addressed experimentally. Finally, the increase in cancer preva-
lence offers a potential explanation as to why animals do not
display constitutively high OPA1 levels that are conversely bene-
ficial against adult life cell death.
Chronic muscle disuse induced by denervation results in mus-
cle atrophy with accompanying mitochondrial alterations (Adhi-
hetty et al., 2007) and network disruption (Romanello et al.,
2010). The anti-atrophic effect of OPA1 overexpression was
not confined to acute muscle loss caused by denervation, butCalso counteracted chronic muscle loss and myopathy caused
by a genetic mitochondrial defect (Civiletto et al., 2015 [this issue
of Cell Metabolism]), further substantiating the key role of OPA1
in the control of muscle atrophy. Mechanistically, OPA1 overex-
pression did not stimulate mitochondrial biogenesis or blunted
autophagy, but it sustained mitochondrial function. OPA1
expression indeed triggered a slight mitochondrial elongation,
which was accompanied by a remarkable increase in respiratory
capacity that correlated with cristae tightness (Cogliati et al.,
2013). Thus, maintenance of mitochondrial cristae seems a
feasible strategy to counteract muscular atrophy, an emerging
medical problem in the aging society.
In addition to skeletal muscle, brain and heart are also high-en-
ergy-demanding tissues where mitochondrial dysfunction is
detrimental. Indeed, ischemia and I/R injury are associated
with a dramatic change in mitochondrial morphology and ultra-
structure (Calo et al., 2013). In addition to its role in apoptosis,
mitochondrial dynamics has recently been implied in necrosis
and necroptosis (Orogo and Gustafsson, 2013; Wang et al.,
2012). Mild OPA1 overexpression was sufficient to improve
enzymatic parameters associated with tissue damage in res-
ponse to ischemic injury. Our results suggest that cristae remod-
eling is central also to propagate necrotic damage, and that its
prevention can ameliorate the ischemic damage outcome.
Notably, OPA1 overexpression did not increase brain or heart
vascularization (data not shown), suggesting a direct effect on
the mechanisms of ischemic cell damage. During muscle atro-
phy as well as heart I/R, long OPA1 forms appear to be cleaved,
presumably by the stress-activated ATP-independent metallo-
protease OMA1 (Baker et al., 2014), to inactivate OPA1 function
that depends in full (Anand et al., 2014) or at least partially (Cipo-
lat et al., 2006) on its long membrane inserted forms. Since sta-
bilization of long OPA1 in Opa1tg mice was associated with I/R
and muscular atrophy protection, it is tempting to speculate
that OPA1 cleavage inhibitors could be cardio and muscle pro-
tective. Finally, the importance of OPA1 in brain and muscle is
further corroborated by the finding that its overexpression ame-
liorates two mouse models of mitochondrial diseases character-
ized by profound neurological and muscular defects (Civiletto
et al., 2015 [this issue of Cell Metabolism]).
Opa1tg hearts at 9months are hypertrophic. Our analysis failed
to reveal any histological or functional sign of maladaptive hyper-
trophy or of increased afterload, one of the most common
causes of hypertrophy. We can speculate thatOpa1 overexpres-
sion results in physiological hypertrophy because it blunts
normal atrophic processes also in the heart, or that the improved
Opa1tg mouse motor performance results in an endurance
training type of hypertrophy, or that the amelioratedOpa1tgmito-
chondrial function directly results in increased myocardial mass,
directly linking mitochondrial function to physiological hypertro-
phy. Irrespective of its underlying mechanism, the observed hy-
pertrophy does not account forOpa1tg heart protection from I/R,
measured in isolated preparations and before its onset.
The liver, where Fas is constitutively expressed on hepato-
cytes (Ogasawara et al., 1993), is very sensitive to Fas-mediated
apoptosis. Because hepatocytes are type II cells in which
Fas-induced death is dependent on the mitochondrial pathway,
Fas receptor activation in the liver has been widely employed
to study apoptosis in vivo (Rodriguez et al., 1996; Yin et al.,ell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authors 841
1999; Wei et al., 2001). Notably, OPA1 overexpression also pro-
tected from Fas-mediated hepatocellular apoptosis.While OPA1
expression did not interfere with Bax, Bak mediated outer mem-
brane permeabilization, and it blunted cytochrome c release
in vitro and in vivo by counteracting its intramitochondrial redis-
tribution during cristae remodeling.
Our work unravels a role for OPA1 and mitochondrial cristae
remodeling in multiple forms of cell death in vivo. The analysis
of a mouse model of mild, targeted OPA1 overexpression ex-
tends the types of cell death controlled by cristae remodeling
beyond apoptosis, indicates a crucial role for mitochondrial
ultrastructure in tissue adaptation to pathological stimuli, and
offers a proof of principle for therapies aimed at ameliorating
mitochondrial cristae in acute and chronic diseases.
EXPERIMENTAL PROCEDURES
Generation of Opa1tg Mice
Experimental procedures for the generation of Opa1tg mice were described
(Cogliati et al., 2013). Opa1tg mice were initially developed in a mixed genetic
background of C57BL/6 3 Sv129Ola and were backcrossed to C57BL/6 and
Sv129 for more than ten generations. The genotype was determined by anal-
ysis of DNA extracted from tail biopsies via PCR. All procedures were autho-
rized by the Office Veterinaire Cantonal of Geneva (1034/3703/2 to L.S.) and
the CEASA of the University of Padova (32/2011 to L.S.).
Echocardiography
Echocardiography was performed in adult (5 and 9 months)Opa1tg (n = 6) and
age- and sex-matched littermate controls (n = 6) using a Vevo 2100 (VisualSon-
ics, Toronto) system equipped with a 30-MHz transducer. Anesthesia was
induced with 3% isoflurane, maintained with 1.5% isoflurane during constant
monitoring of temperature, respiration rate, and ECG. Details on echocardiog-
raphy analysis can be found in Supplemental Experimental Procedures.
Muscle Denervation
Denervation was performed in 5-month-old males by cutting the left hind limb
sciatic nerve, with the right hind limb being used as control. At 10 days after
denervation animals were sacrificed by cervical dislocation, and muscles
were utilized for histological experiments or gene expression studies.
Heart I/R
Heart I/R was performed using a nonrecirculating Langendorff model (Barbato
et al., 1996). The heartswere rapidly excised fromcervical-dislocated 5months
sex-matched animals and perfused retrogradely for 10 min with a bicarbonate
buffer (118.5 mM NaCl, 3.1 mM KCl, 1.18 mM KH2PO4, 25.0 mM NaHCO3,
1 mM MgCl2, 1.4 mM CaCl2, and 5.6 mM glucose) insufflated with 37
C
95% O2-5% CO2 (pH 7.4) at a constant flux of 5 ml/min. After 40 min of
ischemia, hearts were reperfused for 15 min. Coronary effluent during the re-
perfusion period was collected to measure LDH. At the end of reperfusion the
hearts were quickly immersed into PBS supplemented with 0.5% Triton X-100
and homogenized for total LDH measurement.
Brain Ischemia
Animals were sacrificed 3 days after middle cerebral artery (MCA) occlusion.
MCA ligation surgery in mice and 2,3,5-Triphenyltetrazolium chloride (TTC)
staining for quantification of infarct volumes were performed as described
(Colak et al., 2011).
Fas-Induced Apoptosis
Male littermates 3 months old of the indicated genotypes were tail vein in-
jected with an activating anti-Fas antibody (JO2, 0.25 mg/g body weight in
sterile saline solution, BD Pharmingen) or with sterile saline solution as a con-
trol. The animals were monitored and sacrificed 24 hr after injection for liver
biochemistry or histology and clinical chemistry. Blood samples were
collected in BD Microtainer PST LH Tubes and centrifuged at 6,000 g for842 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authors10 min to separate plasma. Plasma levels of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) were determined using stan-
dard, Clinical Pathology Accredited and ISO9001:2008-certified procedures
at the Department of Laboratory Medicine, Padova University Hospital. Liver
samples were immediately frozen in liquid nitrogen for biochemical analysis
or processed to paraformaldehyde (PFA) fixation for subsequent histological
analysis and TUNEL staining.
Histology and Immunofluorescence Staining
Heart, muscle, and liver tissues were fixed in 1% PFA in PBS at room temper-
ature for 15 min, equilibrated in a sucrose gradient, frozen in liquid nitrogen,
sectioned, and processed for histological and immunofluorescence analyses.
Sections (10 microns) were obtained with a cryostat (Leica CM1850, Leica Mi-
crosystems, Wetzlar) and incubated with primary antibodies diluted in PBS
supplemented with 1% BSA and 0.5% Triton X-100 overnight at 4C. Details
on the antibodies used can be found in Supplemental Experimental Proce-
dures. Livers were also cut into small pieces and fixed overnight at 4C in
4% PFA in PBS and then dehydrated through serial ethanol concentrations
for paraffin embedding. Paraffin-embedded livers were used for TUNEL and
H&E staining. TUNEL assay was performed by using the ApopTag peroxidase
in situ apoptosis detection system, following the procedure suggested by the
manufacturer (Chemicon). For COX and SDH histochemical analysis, tissues
were frozen in liquid nitrogen pre-cooled isopentane, and 8-mm-thick sections
were stained as described (Sciacco and Bonilla, 1996).
Biochemical Analysis of MRC Complexes
Skeletal and cardiac muscle samples were snap-frozen in liquid nitrogen and
homogenized in 10 mM phosphate buffer (pH 7.4). The spectrophotometric
activities of CI, CII, CIII, and CIV, as well as citrate synthase (CS), were
measured as described (Bugiani et al., 2004).
Gene Expression Analyses
Total RNA was prepared from gastrocnemius muscles using TRIzol (Invitro-
gen). cDNA was generated from 0.4 mg of RNA reverse-transcribed with Su-
perScript III Reverse Transcriptase (Invitrogen). Duplicates of cDNA samples
were then amplified on the 7900HT Fast Real-Time PCR System (Applied Bio-
systems) using the Power SYBR Green RT-PCR kit (Applied Biosystems). All
data were normalized to GAPDH expression and plotted in arbitrary units as
mean ± SEM of independent experiments. The oligonucleotide primers used
can be found in Supplemental Experimental Procedures.
Assays of Mitochondrial Membrane Potential
Mitochondrial membrane potential in isolated flexor digitorum brevis (FDB)
muscle fibers was measured by intensity of TMRM fluorescence. Details can
be found in Supplemental Experimental Procedures.
In Vitro Mitochondrial Assays
Liver andmusclemitochondria were isolated as described (Frezza et al., 2007).
Cytochrome c redistribution and release in response to 40 pmol cBID/mgmito-
chondria was performed as described (Scorrano et al., 2002). Mitochondrial
oxygen consumption was measured with a Clark type oxygen electrode (Han-
satech Instruments) as described (Frezza et al., 2007). Details on mitochondria
Ca2+ retention capacity andmitochondrial membrane potential measurements
can be found in Supplemental Experimental Procedures.
Biochemistry
For protein crosslinking, mitochondria were treated as indicated with 1 mM
EDC or 1 mM BMH as described (Frezza et al., 2006). For SDS-PAGE, equal
amounts of mitochondrial proteins were separated on 3%–8% Tris-acetate
or 4%–12% Tris-MES (NuPAGE, Invitrogen) polyacrilamide gel, transferred
onto PVDF membranes (Bio-Rad), and probed using the indicated primary an-
tibodies and isotype-matched secondary antibodies conjugated to horse-
radish peroxidase. Signal was detected with ECL (Amersham). Details on
the antibodies used can be found in Supplemental Experimental Procedures.
Densitometry was performed using ImageJ.
To detect OPA1 oligomers by BN-PAGE, mitochondria were resuspended
in an appropriated volume of Buffer D (1 M 6-aminohexanoic acid, 1.25% V/V
digitonin, 50 mM Bis-Tris-HCl [pH 7]) at a final concentration of 10 mg/ml.
Following centrifugation, the supernatant was collected, and 5% Serva Blue
G dye in 1 M 6-aminohexanoic acid was added to one-third of the final
volume of the sample. Equal amounts (100 mg) of mitochondrial proteins
were separated on a 3%–12% gradient BNGE (Invitrogen) as described
(Scha¨gger, 1995).
Determination of ROS Production
Mitochondrial ROS levels were analyzed in cells incubated for 24 hr in DMEM
containing glucose (4.5 mg/ml) or galactose (0.9 mg/ml). Cells were stained
with 2 mM MitoSOX (Invitrogen) in HBSS for 30 min at 37C and rinsed, and
the fluorescence was assessed by flow cytometry using the FL1 channel of
a FACSCalibur (BD Pharmingen) cytometer.
Transmission EM
Heart specimens from mice of the indicated genotype were fixed in 2% form-
aldehyde, 2.5% (V/V) glutaraldehyde in 0.1MNa-cacodylate (pH 7.4) for 2 hr at
room temperature and then overnight at 4C. EMwas performed as described
(Scorrano et al., 2002). Thin sections were imaged on a Tecnai-20 electron mi-
croscope (Philips-FEI).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2015.05.007.
AUTHOR CONTRIBUTIONS
T.V. performed experiments, analyzed data, and wrote the manuscript; M.E.S.
generated the Opa1tg colony and performed experiments; V.R. analyzed
denervated muscles; T.Z. analyzed hearts; R.Q.-C. performed ROS measure-
ments; M. Semenzato performed RT-PCR analyses; R.M. helped perform
heart ischemia reperfusion; V.C. performed mitochondrial in vitro assays;
G.C. performed respiratory chain activity staining; P.P. helped perform echo-
cardiography; C.V., M.Z., F.D.L., M.M., and M. Sandri supervised research,
analyzed data, and contributed to writing; and L.S. conceived the project, su-
pervised research, analyzed data, and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Drs. M. Zaninotto and R. Venturini (Deptartment of Laboratory Med-
icine, University of Padova) for ALT and ASTmeasurements, Drs. F. Caicci and
F. Boldrin (Department of Biology, University of Padova) for EM sample prep-
aration, Dr. S. Cogliati (CSIC, Madrid) for helpful discussions, and Dr. E.
Schrepfer (Department of Biology, University of Padova) for the graphical
abstract preparation. L.S. is a Senior Scientist of the Dulbecco-Telethon Insti-
tute. This work was supported by Telethon-Italy GPP10005, GGP12162,
GGP14187A; AIRC Italy, ERC FP7-282280, FP7 CIG PCIG13-GA-2013-
618697; Italian Ministry of Research, FIRB RBAP11Z3YA_005; Swiss National
Foundation, 31-118171 to L.S.; and ERC FP7-282310, Fondation Leducq toM.
Sandri.
Received: September 30, 2014
Revised: February 18, 2015
Accepted: May 4, 2015
Published: June 2, 2015
REFERENCES
Abel, E.D., and Doenst, T. (2011). Mitochondrial adaptations to physiological
vs. pathological cardiac hypertrophy. Cardiovasc. Res. 90, 234–242.
Adhihetty, P.J., O’Leary, M.F.N., Chabi, B., Wicks, K.L., and Hood, D.A. (2007).
Effect of denervation on mitochondrially mediated apoptosis in skeletal mus-
cle. J. Appl. Physiol. 102, 1143–1151.
Almind, K., and Kahn, C.R. (2004). Genetic determinants of energy expenditure
and insulin resistance in diet-induced obesity in mice. Diabetes 53, 3274–
3285.CAnand, R., Wai, T., Baker, M.J., Kladt, N., Schauss, A.C., Rugarli, E., and
Langer, T. (2014). The i-AAA protease YME1L and OMA1 cleave OPA1 to bal-
ance mitochondrial fusion and fission. J. Cell Biol. 204, 919–929.
Baker, M.J., Lampe, P.A., Stojanovski, D., Korwitz, A., Anand, R., Tatsuta, T.,
and Langer, T. (2014). Stress-induced OMA1 activation and autocatalytic turn-
over regulate OPA1-dependent mitochondrial dynamics. EMBO J. 33,
578–593.
Barbato, R., Menabo`, R., Dainese, P., Carafoli, E., Schiaffino, S., and Di Lisa, F.
(1996). Binding of cytosolic proteins to myofibrils in ischemic rat hearts. Circ.
Res. 78, 821–828.
Basso, E., Fante, L., Fowlkes, J., Petronilli, V., Forte, M.A., and Bernardi, P.
(2005). Properties of the permeability transition pore in mitochondria devoid
of Cyclophilin D. J. Biol. Chem. 280, 18558–18561.
Bugiani, M., Invernizzi, F., Alberio, S., Briem, E., Lamantea, E., Carrara, F.,
Moroni, I., Farina, L., Spada, M., Donati, M.A., et al. (2004). Clinical and molec-
ular findings in children with complex I deficiency. Biochim. Biophys. Acta
1659, 136–147.
Calo, L., Dong, Y., Kumar, R., Przyklenk, K., and Sanderson, T.H. (2013).
Mitochondrial dynamics: an emerging paradigm in ischemia-reperfusion
injury. Curr. Pharm. Des. 19, 6848–6857.
Cereghetti, G.M., Stangherlin, A., Martins de Brito, O., Chang, C.R.,
Blackstone, C., Bernardi, P., and Scorrano, L. (2008). Dephosphorylation by
calcineurin regulates translocation of Drp1 to mitochondria. Proc. Natl.
Acad. Sci. USA 105, 15803–15808.
Chen, H., Detmer, S.A., Ewald, A.J., Griffin, E.E., Fraser, S.E., and Chan, D.C.
(2003). Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion
and are essential for embryonic development. J. Cell Biol. 160, 189–200.
Cipolat, S., Martins de Brito, O., Dal Zilio, B., and Scorrano, L. (2004). OPA1
requires mitofusin 1 to promote mitochondrial fusion. Proc. Natl. Acad. Sci.
USA 101, 15927–15932.
Cipolat, S., Rudka, T., Hartmann, D., Costa, V., Serneels, L., Craessaerts, K.,
Metzger, K., Frezza, C., Annaert, W., D’Adamio, L., et al. (2006). Mitochondrial
rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-
dependent cristae remodeling. Cell 126, 163–175.
Civiletto, G., Varanita, T., Cerutti, R., Gorletta, T., Barbaro, S., Marchet, S.,
Lamperti, C., Viscomi, C., Scorrano, L., and Zeviani, M. (2015). Opa1 overex-
pression ameliorates the phenotype of two mitochondrial disease mouse
models. Cell Metab. 21, this issue, 845–854.
Cogliati, S., Frezza, C., Soriano, M.E., Varanita, T., Quintana-Cabrera, R.,
Corrado, M., Cipolat, S., Costa, V., Casarin, A., Gomes, L.C., et al. (2013).
Mitochondrial cristae shape determines respiratory chain supercomplexes as-
sembly and respiratory efficiency. Cell 155, 160–171.
Colak, G., Filiano, A.J., and Johnson, G.V. (2011). The application of perma-
nent middle cerebral artery ligation in the mouse. J. Vis. Exp. http://dx.doi.
org/10.3791/3039.
Danial, N.N., and Korsmeyer, S.J. (2004). Cell death: critical control points. Cell
116, 205–219.
Danial, N.N., Gramm, C.F., Scorrano, L., Zhang, C.Y., Krauss, S., Ranger,
A.M., Datta, S.R., Greenberg, M.E., Licklider, L.J., Lowell, B.B., et al. (2003).
BAD and glucokinase reside in a mitochondrial complex that integrates glycol-
ysis and apoptosis. Nature 424, 952–956.
Davies, V.J., Hollins, A.J., Piechota, M.J., Yip, W., Davies, J.R., White, K.E.,
Nicols, P.P., Boulton, M.E., and Votruba, M. (2007). Opa1 deficiency in a
mouse model of autosomal dominant optic atrophy impairs mitochondrial
morphology, optic nerve structure and visual function. Hum. Mol. Genet. 16,
1307–1318.
De Meyer, G.R.Y., De Keulenaer, G.W., and Martinet, W. (2010). Role of auto-
phagy in heart failure associated with aging. Heart Fail. Rev. 15, 423–430.
DiMauro, S., and Schon, E.A. (2003). Mitochondrial respiratory-chain dis-
eases. N. Engl. J. Med. 348, 2656–2668.
Du, X.J. (2004). Gender modulates cardiac phenotype development in genet-
ically modified mice. Cardiovasc. Res. 63, 510–519.
Du, X.J. (2007). Divergence of hypertrophic growth and fetal gene profile: the
influence of beta-blockers. Br. J. Pharmacol. 152, 169–171.ell Metabolism 21, 834–844, June 2, 2015 ª2015 The Authors 843
Frank, S., Gaume, B., Bergmann-Leitner, E.S., Leitner, W.W., Robert, E.G.,
Catez, F., Smith, C.L., and Youle, R.J. (2001). The role of dynamin-related pro-
tein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 1, 515–525.
Frenzel, A., Grespi, F., Chmelewskij, W., and Villunger, A. (2009). Bcl2 family
proteins in carcinogenesis and the treatment of cancer. Apoptosis 14,
584–596.
Frey, T.G., and Mannella, C.A. (2000). The internal structure of mitochondria.
Trends Biochem. Sci. 25, 319–324.
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G.V.,
Rudka, T., Bartoli, D., Polishuck, R.S., Danial, N.N., De Strooper, B., and
Scorrano, L. (2006). OPA1 controls apoptotic cristae remodeling indepen-
dently from mitochondrial fusion. Cell 126, 177–189.
Frezza, C., Cipolat, S., and Scorrano, L. (2007). Organelle isolation: functional
mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc.
2, 287–295.
Griparic, L., and van der Bliek, A.M. (2001). The many shapes of mitochondrial
membranes. Traffic 2, 235–244.
Hackenbrock, C.R. (1966). Ultrastructural bases for metabolically linked me-
chanical activity in mitochondria. I. Reversible ultrastructural changes with
change in metabolic steady state in isolated liver mitochondria. J. Cell Biol.
30, 269–297.
Irwin, W.A., Bergamin, N., Sabatelli, P., Reggiani, C., Megighian, A., Merlini, L.,
Braghetta, P., Columbaro, M., Volpin, D., Bressan, G.M., et al. (2003).
Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI
deficiency. Nat. Genet. 35, 367–371.
Landes, T., Emorine, L.J., Courilleau, D., Rojo, M., Belenguer, P., and Arnaune´-
Pelloquin, L. (2010). The BH3-only Bnip3 binds to the dynamin Opa1 to pro-
mote mitochondrial fragmentation and apoptosis by distinct mechanisms.
EMBO Rep. 11, 459–465.
Martinou, I., Desagher, S., Eskes, R., Antonsson, B., Andre´, E., Fakan, S., and
Martinou, J.C. (1999). The release of cytochrome c from mitochondria during
apoptosis of NGF-deprived sympathetic neurons is a reversible event.
J. Cell Biol. 144, 883–889.
Murphy, E., and Steenbergen, C. (2008). Mechanisms underlying acute pro-
tection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88, 581–609.
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai,
T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993). Lethal effect of the
anti-Fas antibody in mice. Nature 364, 806–809.
Orogo, A.M., and Gustafsson, A.B. (2013). Cell death in the myocardium: my
heart won’t go on. IUBMB Life 65, 651–656.
Palmer, C.S., Osellame, L.D., Laine, D., Koutsopoulos, O.S., Frazier, A.E., and
Ryan, M.T. (2011). MiD49 and MiD51, new components of the mitochondrial
fission machinery. EMBO Rep. 12, 565–573.
Pena, J.C., Rudin, C.M., and Thompson, C.B. (1998). A Bcl-xL transgene pro-
motes malignant conversion of chemically initiated skin papillomas. Cancer
Res. 58, 2111–2116.
Powers, S.K., Kavazis, A.N., and McClung, J.M. (2007). Oxidative stress and
disuse muscle atrophy. J. Appl. Physiol. 102, 2389–2397.
Rizzuto, R., Bernardi, P., and Pozzan, T. (2000). Mitochondria as all-round
players of the calcium game. J. Physiol. 529, 37–47.
Rodriguez, I., Matsuura, K., Khatib, K., Reed, J.C., Nagata, S., and Vassalli, P.
(1996). A bcl-2 transgene expressed in hepatocytes protects mice from fulmi-
nant liver destruction but not from rapid death induced by anti-Fas antibody
injection. J. Exp. Med. 183, 1031–1036.844 Cell Metabolism 21, 834–844, June 2, 2015 ª2015 The AuthorsRomanello, V., Guadagnin, E., Gomes, L., Roder, I., Sandri, C., Petersen, Y.,
Milan, G., Masiero, E., Del Piccolo, P., Foretz, M., et al. (2010). Mitochondrial
fission and remodelling contributes to muscle atrophy. EMBO J. 29, 1774–
1785.
Sandri, M. (2008). Signaling in muscle atrophy and hypertrophy. Physiology
(Bethesda) 23, 160–170.
Sandri, M. (2013). Protein breakdown in muscle wasting: role of autophagy-
lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45, 2121–2129.
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z.P., Lecker, S.H.,
Goldberg, A.L., and Spiegelman, B.M. (2006). PGC-1alpha protects skeletal
muscle from atrophy by suppressing FoxO3 action and atrophy-specific
gene transcription. Proc. Natl. Acad. Sci. USA 103, 16260–16265.
Santel, A., Frank, S., Gaume, B., Herrler, M., Youle, R.J., and Fuller, M.T.
(2003). Mitofusin-1 protein is a generally expressed mediator of mitochondrial
fusion in mammalian cells. J. Cell Sci. 116, 2763–2774.
Scha¨gger, H. (1995). Native electrophoresis for isolation ofmitochondrial oxida-
tive phosphorylation protein complexes. Methods Enzymol. 260, 190–202.
Sciacco, M., and Bonilla, E. (1996). Cytochemistry and immunocytochemistry
of mitochondria in tissue sections. Methods Enzymol. 264, 509–521.
Scorrano, L., Ashiya,M., Buttle, K.,Weiler, S., Oakes, S.A., Mannella, C.A., and
Korsmeyer, S.J. (2002). A distinct pathway remodels mitochondrial cristae and
mobilizes cytochrome c during apoptosis. Dev. Cell 2, 55–67.
Seo, A.Y., Joseph, A.M., Dutta, D., Hwang, J.C.Y., Aris, J.P., and
Leeuwenburgh, C. (2010). New insights into the role of mitochondria in aging:
mitochondrial dynamics and more. J. Cell Sci. 123, 2533–2542.
Siu, P.M., and Alway, S.E. (2005). Mitochondria-associated apoptotic signal-
ling in denervated rat skeletal muscle. J. Physiol. 565, 309–323.
Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev.
15, 2922–2933.
Wang, Z., Jiang, H., Chen, S., Du, F., and Wang, X. (2012). The mitochondrial
phosphatase PGAM5 functions at the convergence point of multiple necrotic
death pathways. Cell 148, 228–243.
Wasilewski, M., and Scorrano, L. (2009). The changing shape of mitochondrial
apoptosis. Trends Endocrinol. Metab. 20, 287–294.
Wei, M.C., Lindsten, T., Mootha, V.K., Weiler, S., Gross, A., Ashiya, M.,
Thompson, C.B., and Korsmeyer, S.J. (2000). tBID, a membrane-targeted
death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14,
2060–2071.
Wei, M.C., Zong,W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross,
A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., and Korsmeyer, S.J.
(2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science 292, 727–730.
Yamaguchi, R., Lartigue, L., Perkins, G., Scott, R.T., Dixit, A., Kushnareva, Y.,
Kuwana, T., Ellisman, M.H., and Newmeyer, D.D. (2008). Opa1-mediated
cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and
independent of Bak oligomerization. Mol. Cell 31, 557–569.
Yin, X.M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K.A., and
Korsmeyer, S.J. (1999). Bid-deficient mice are resistant to Fas-induced hepa-
tocellular apoptosis. Nature 400, 886–891.
Zhang, Z., Wakabayashi, N., Wakabayashi, J., Tamura, Y., Song, W.J.,
Sereda, S., Clerc, P., Polster, B.M., Aja, S.M., Pletnikov, M.V., et al. (2011).
The dynamin-related GTPase Opa1 is required for glucose-stimulated ATP
production in pancreatic beta cells. Mol. Biol. Cell 22, 2235–2245.
